Escitalopram
13 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
13
Ongoing
2
Recruiting
1
Completed
8
Sites
54
Countries
5
Endpoints
88
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 88 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 8 of 88 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
5
2
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
13 of 13
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| S-CitADEscitalopram for Agitation in Alzheimer's Disease | Escitalopram Alzheimer’s disease | Alzheimer's disease | Ph 3 | Active, not recruiting | 29 | Apr 2024 | 2 | |
| DESEPDementia Antipsychotics And Antidepressants Discontinuation Study | Citalopram, Escitalopram, Paroxetine, Risperidone, Sertraline Alzheimer’s disease, Vascular cognitive impairment / dementia | Multiple dementia etiologies | Ph 4 | Completed | 8 | Dec 2010 | 1 | |
| ESADProgression Delaying Effect of Escitalopram in Alzheimer's Disease | Escitalopram Alzheimer’s disease | Alzheimer's disease | Not applicable | Completed | 4 | Sep 2011 | - | results |
| NCT00260624Escitalopram Treatment of Patients With Agitated Dementia | Escitalopram Alzheimer’s disease | Alzheimer's disease | Ph 4 | Completed | 3 | Dec 2006 | - | |
| NCT00488670Escitalopram and Depression in Elderly Alzheimer's Patients | Escitalopram Alzheimer’s disease | Alzheimer's disease | Ph 3 | Terminated | 2 | Jun 2011 | - | |
| NCT05004987Aβ Dynamics in LLMD | Escitalopram Alzheimer’s disease | MMSE ≥27 | Ph 4 | Recruiting | 2 | Dec 2026 | - | |
| NCT03274817A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol | Escitalopram, Venlafaxine Alzheimer’s disease, MCI / preclinical Alzheimer’s | Study partner/caregiver required | Ph 1 | Terminated | 1 | Sep 2019 | - | |
| NCT00229333Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia, and Mixed Vascular and Alzheimer's Dementia | Escitalopram Alzheimer’s disease, Vascular cognitive impairment / dementia | Multiple dementia etiologies | Ph 4 | Unknown | 1 | - | - | |
| EscBPSDEscitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone | Escitalopram, Risperidone Alzheimer’s disease | MMSE 5-26 | Ph 4 | Completed | 1 | Apr 2010 | 1 | |
| EscitalopramEscitalopram for the Treatment of Depression in Alzheimer's Disease | Escitalopram Alzheimer’s disease | Alzheimer's disease | Ph 4 | Completed | 1 | Jul 2014 | - | |
| NCT01876823Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment | Escitalopram, Memantine Alzheimer’s disease, MCI / preclinical Alzheimer’s | Age 50-90 | Ph 2/3 | Completed | 1 | Mar 2010 | 49 | results |
| NCT00177671Antidepressant Medication Plus Donepezil for Treating Late-life Depression | Donepezil, Duloxetine, Escitalopram, Venlafaxine Mixed / unspecified dementia | Age ≥65 | Ph 4 | Completed | 1 | Sep 2009 | 5 | results |
| NCT00433121Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD | Citalopram, Escitalopram, Haloperidol, Olanzapine, Quetiapine, Risperidone, Sertraline Alzheimer’s disease, Vascular cognitive impairment / dementia | Multiple dementia etiologies | Ph 4 | Completed | 1 | Aug 2007 | - |
Showing 1-13 of 13 trials